Sentences with phrase «developing novel therapeutic agents»

«Collaborating with the outstanding scientists at Lundbeck, offers great hope for discovering what triggers these diseases and developing novel therapeutic agents.»

These isogenic cell lines can be used not only to understand the cellular consequences of disease mutations, but also to perform high throughput genetic and pharmacological screens to both understand the underlying pathological mechanisms and to develop novel therapeutic agents to prevent or treat such diseases.

Not exact matches

After a successful postdoc at the Ontario Cancer Institute, where he developed a proprietary platform for the discovery of novel cancer therapeutic agents, Bray was asked to join the former Amgen Research Institute in Toronto (now called the Advanced Medical Discovery Institute and no longer part of the parent company) as the head of their quantitative biology group and act as liaison to Amgen Inc. in California.

In a study to be published online February 2 in Nature Communications, scientists from the Icahn School of Medicine at Mount Sinai describe an extensive analysis of novel grape - derived compounds, dihydrocaffeic acid (DHCA) and malvidin - 3» - O - glucoside (Mal - gluc), which might be developed as therapeutic agents for the treatment of depression.

As part of his research, Dr. Chang has defined several novel mechanisms and mediators of action of probiotic organisms that are currently being developed as therapeutic agents.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma